NUP42

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, NUP42 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NUP42 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher NUP42 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NUP42 expression acts as an unfavorable survival marker.

PRAD and SKCM are the cancer types where NUP42 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
PRADDFSMedianAll0.0850.774<.0016view →
SKCMDFSMedianAll0.3870.623.0224view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

NUP42–PRAD (DFS)

Kaplan–Meier survival curve for NUP42 mutant vs wild-type samples in PRAD.

Open the PRAD breakdown →

Exploration